ProCE Banner Activity

CE

NED TALK 2022: Optimizing Melanoma Care to Improve Patient Outcomes

Multimedia
Watch this on-demand webcast from a nursing education day (NED) webinar series on improving outcomes for patients with melanoma using targeted therapies and immunotherapies.

Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credits

Nurses: 1.50 Nursing contact hours

Released: February 22, 2022

Expiration: February 21, 2023

No longer available for credit.

Share

Faculty

Kathleen Madden

Kathleen Madden, FNP, MSN, AOCNP, APHN

Melanoma Program
NYU Langone Perlmutter Cancer Center
New York, NY

Suzanne McGettigan

Suzanne McGettigan, MSN, AOCN, ANP-BC

Nurse Practitioner, Clinical Manager
Division of Hematology-Oncology
Abramson Cancer Center
Penn Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Krista M. Rubin

Krista M. Rubin, MS, RN, FNP-BC

Nurse Practitioner
Center for Melanoma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Target Audience

This educational program is intended for nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, and oncology nurses.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Review the clinical efficacy and safety profiles associated with targeted therapies and immunotherapies across the melanoma treatment settings
  • Recall current indications for targeted therapies and immunotherapies across the melanoma treatment settings
  • Develop a proactive management plan for early recognition and appropriate management of AEs associated with targeted and immunotherapies to support quality of life and continuation of treatment
  • Evaluate nursing strategies to optimize patient care, including—but not limited to—patient counseling for management of treatment-related AEs and the importance of adherence to treatment

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Kathleen Madden, FNP, MSN, AOCNP, APHN

Melanoma Program
NYU Langone Perlmutter Cancer Center
New York, NY

Kathy Madden, MSN, FNP-BC, AOCNP, APHN, has disclosed that she has received consulting fees from Novartis and Pfizer.

Suzanne McGettigan, MSN, AOCN, ANP-BC

Nurse Practitioner, Clinical Manager
Division of Hematology-Oncology
Abramson Cancer Center
Penn Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Suzanne McGettigan, MSN, AOCN, ANP-BC, has disclosed that she has received fees for non-CME/CE services from Bristol-Myers Squibb, Merck, and Pfizer.

Krista M. Rubin, MS, RN, FNP-BC

Nurse Practitioner
Center for Melanoma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Krista M. Rubin, MS, RN, FNP-BC, has disclosed that she has received consulting fees from Bristol-Myers Squibb, Eisai, and Merck.

Staff Disclosure

Staff

Jerfiz Constanzo, PhD, MBA

Scientific Director

Jerfiz Constanzo, PhD, MBA, has no relevant conflicts of interest to report.

Kristen Kreider, PA

Kristin Kreider, PA, has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom, has no relevant conflicts of interest to report.

Instructions for Credit

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for maximum of 1.5 hours of AAPA Category 1 CME credit. Approval is valid until February 21, 2023. PAs should only claim commensurate with the extent of their participation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 22, 2022, through February 21, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, confidence, and competence of nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, and oncology nurses surrounding recent improvements in the care of melanoma and in applying those improvements to their patients.